Salivary flow rate · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects (other reported events) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Alopecia, skin toxicity, hot flush, drowsiness, sneezing, hiccupping, dizziness and fatigue reported narratively or only for the amifostine group; insufficient evidence of a difference
Studies not reported
GRADE not reported
Xerostomia (grade >= 2, 0-4 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine may leads to lower xerostomia (grade >= 2, 0-4 scale) compared with no treatment/placebo (low certainty).
3 findings from 1 review
RR 0.35 [0.19, 0.67]
3 studies · 119 participants
Low
RR 0.70 [0.40, 1.23]
7 studies · 682 participants
Low
RR 0.66 [0.48, 0.92]
5 studies · 687 participants
Low
Rescue analgesia · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
1 finding from 1 review
Allergic adverse events · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine may leads to higher allergic response (adverse effect) compared with no treatment/placebo (low certainty).
1 finding from 1 review
Taste disturbance (severe, > 2 on 0-3 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Polaprezinc led to lower taste disturbance (severe, > 2 on 0-3 scale) compared with azulene oral rinse; GRADE not reported.
1 finding from 1 review
Quality of life or participant satisfaction · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
No evidence of a difference in reported adverse events across the three trials (nausea, fever, constipation, diarrhoea, headache, fatigue and others)
3 studies
GRADE not reported
Xerostomia (VAS) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Dry mouth (xerostomia) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Antimicrobial lozenge showed no clear difference in xerostomia compared with placebo; GRADE not reported.
1 finding from 1 review
Quality of life · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Xerostomia (severe) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Polaprezinc led to lower xerostomia (severe) compared with azulene oral rinse; GRADE not reported.
1 finding from 1 review
Dry mouth (xerostomia) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Chinese medicine led to lower xerostomia (dichotomous, Shenqi Fanghou recipe) compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
1 finding from 1 review
Adverse effects · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
It is very uncertain whether topical NSAID (ketoprofen chewing gum) changes pain intensity (VAS 0-100 mm) compared with local anaesthetic (benzocaine chewing gum) (very low certainty).
1 finding from 1 review
Quality of life · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Time off school or work · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
The review found no eligible studies for this question.
1 finding from 1 review
Vomiting · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine may leads to higher vomiting (adverse effect) compared with no treatment/placebo (low certainty).
1 finding from 1 review
Time off school or work · People undergoing orthodontic treatment (any age; 9 to 34 years in included studies)
The review found no eligible studies for this question.
1 finding from 1 review